Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

15xxGCC: PHASE II TRIAL OF THE EP4 RECEPTOR ANTAGONIST, AAT-007 (RQ-07; CJ-023,423) IN ADVANCED SOLID TUMORS

NCT02538432 is registered in ClinicalTrials.gov with University of Maryland, Baltimore as lead sponsor.

NCT NCT02538432
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02538432 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
15xxGCC: PHASE II TRIAL OF THE EP4 RECEPTOR ANTAGONIST, AAT-007 (RQ-07; CJ-023,423) IN ADVANCED SOLID TUMORS
Lead sponsor
University of Maryland, Baltimore
Phase
Phase 2
Overall status
Withdrawn
Start date
June 30, 2017
Completion date
December 31, 2021
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, non-small cell lung cancer, prostate cancer